Evidence map›Paper›PMID 33318611›Full record

ArticleLeukemia2021

Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting.

S Modvig, H Hallböök, H O Madsen, S Siitonen, S Rosthøj, A Tierens, V Juvonen, L T N Osnes, H Vålerhaugen, M Hultdin and 17 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. MRD in ALL: Optimization and Innovations.Current hematologic malignancy reports · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

S ModvigDepartment of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-9113-1097
H HallböökDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
H O MadsenDepartment of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
S SiitonenClinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
S RosthøjSection of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
A TierensLaboratory Medicine Program, University Health Network and University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-5350-8313
V JuvonenDepartment of Clinical Chemistry and Laboratory Division, University of Turku and Turku University Hospital, Turku, Finland.
L T N OsnesDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
H VålerhaugenDepartment of Pathology, Laboratory of Molecular Pathology, Oslo University Hospital, Oslo, Norway.
M HultdinDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
R MatuzevicieneDepartment of Physiology, Biochemistry, Microbiology and Laboratory Medicine, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University and Centre of Laboratory Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
M StoskusHematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
M MarincevicDepartment of Clinical Pathology, Uppsala University, Uppsala, Sweden.
A LilleorgDepartment of Clinical Immunology, North Estonia Medical Centre, Tallinn, Estonia.
M EhingerDepartment of Clinical Genetics and Pathology, Skåne University Hospital and Department of Clinical Sciences, Oncology and Pathology, Lund University, Lund, Sweden.
U Norén-NystrømDepartment of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden.
N ToftDepartment of Hematology, Herlev University Hospital, Herlev, Denmark.
M TaskinenDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, Helsinki University Hospital, Helsinki, Finland.
O G JónssonChildren's Hospital, Landspitali University Hospital, Reykjavik, Iceland.
K PruunsildTallinn Children's Hospital, Tallinn, Estonia.
G VaitkevicieneChildren's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania.
K VettenrantaUniversity of Helsinki and Helsinki University Children´s Hospital, Helsinki, Finland.
B LundDepartment of Pediatrics, St. Olavs University Hospital and Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway.
J AbrahamssonInstitution of Clinical Sciences, Department of Pediatrics, Sahlgrenska University Hospital, Gothenburg, Sweden.
A PorwitDivision Oncology and Pathology, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.
K SchmiegelowDepartment of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet and The Institute of Clinical medicine, The Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-0829-4993
H V MarquartDepartment of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Hanne.Marquart@regionh.dk.ORCID http://orcid.org/0000-0001-9740-6522

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PCR of TCR/Ig gene rearrangements is considered the method of choice for minimal residual disease (MRD) quantification in BCP-ALL, but flow cytometry analysis of leukemia-associated immunophenotypes (FCM-MRD) is faster and biologically more informative. FCM-MRD performed in 18 laboratories across seven countries was used for risk stratification of 1487 patients with BCP-ALL enrolled in the NOPHO ALL2008 protocol. When no informative FCM-marker was available, risk stratification was based on real-time quantitative PCR. An informative FCM-marker was found in 96.2% and only two patients (0.14%) had non-informative FCM and non-informative PCR-markers. The overall 5-year event-free survival was 86.1% with a cumulative incidence of relapse (CIR

Indexed as

AdolescentAdultChildChild, PreschoolFemaleFlow CytometryHumansImmunophenotypingInfantMaleMiddle AgedNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor Cells, B-LymphoidRecurrenceYoung Adult

Identifiers

PMID33318611
PMCPMC8257490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.